Noom is the latest digital health company to jump into the off-label weight loss drug market to make medications more accessible to consumers. | Noom is the latest digital health company to jump into the off-label weight loss drug market to make medications more accessible to consumers.

In July, the U.S. Food and Drug Administration warned that people are overdosing on compounded semaglutide injectable products.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.

Many of the calls stem from individuals mistakenly taking the wrong dose of the compounded version of semaglutide.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.

Weight-loss drugs like Ozempic are booming in popularity, but experts warn they aren't silver bullets for obesity.